MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562848251393074

Медицинская библиотека · Therapeutic advances in gastroenterology · 2025

Toward personalized therapeutic drug monitoring of ustekinumab in Crohn's disease: influence of previous exposure to biologics.

Kwon Yiyoung, Kim Yoon Zi, Jeong Tae Jong, Kim Seon Young, Kim Hansol, Kim Eun Sil, Choe Yon Ho, Kim Mi Jin

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Unlike infliximab, ustekinumab (UST) has shown inconsistent associations between drug concentration and clinical efficacy across studies, with varying cutoff therapeutic trough levels (TLs) proposed.

OBJECTIVES

Given that patients have different histories of biologic use, we aimed to evaluate whether therapeutic TLs of ustekinumab require optimization in patients with Crohn's disease.

DESIGN

Cohort study.

METHODS

To assess whether ustekinumab has a potential therapeutic cutoff value, we evaluated and compared its 1-year TLs in 14 biologic-naïve patients and in 26 patients who were prescribed the drug after experiencing a loss of response to previous biologic therapies.

RESULTS

The mean TL in the biologic-naïve patients was 3.41 µg/mL, which was significantly higher than that in the biologic-experienced patients (1.46 µg/mL; p = 0.007). The duration of prior biologic therapy and disease activity correlated with the ustekinumab TLs. With regard to the optimal cutoff value for predicting deep remission at 1 year, the threshold was 2.34 µg/mL for the biologic-naïve patients (area under the receiver operating characteristic curve (AUC) = 0.909, p < 0.001) and 1.18 µg/mL for the biologic-experienced patients (AUC = 0.892, p < 0.001).

CONCLUSION

Ustekinumab TLs in patients may differ according to their prior exposure to biologic agents and disease activity. Accordingly, rather than applying a uniform threshold, ustekinumab levels should be interpreted using individualized, patient-specific strategies in clinical practice.

Для цитирования: Kwon Yiyoung, Kim Yoon Zi, Jeong Tae Jong, Kim Seon Young, Kim Hansol, Kim Eun Sil, Choe Yon Ho, Kim Mi Jin. Toward personalized therapeutic drug monitoring of ustekinumab in Crohn's disease: influence of previous exposure to biologics.. Therapeutic advances in gastroenterology. 2025. DOI: 10.1177/17562848251393074.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.